BioSpace News Archive

Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

Autonomix Medical, Inc., a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, announced changes to its executive leadership team to support its next pivotal phase of development.

Keros Therapeutics, Inc. announced changes to its Board of Directors and Executive Committee, effective July 1, 2024.

Vaxart, Inc. provided business and cash runway updates as the Company continues to advance its oral pill vaccine platform.

Kyverna Therapeutics, Inc. (Kyverna) announced today the publication in Proceedings of the National Academy of Sciences (PNAS)1 of a report describing the first use of KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, in a 69-year-old patient suffering from treatment-refractory stiff-person syndrome (SPS) as part of a named-patient use in Germany for critically ill individuals who fail conventional therapies.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.

GENFIT announced the inclusion of NIS2+® as a key tool for detecting at-risk MASH1 in the European Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease.

Veru Inc., a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, would like to remind shareholders to vote in connection with the Company’s upcoming annual meeting of shareholders, to be held on Tuesday, June 18, 2024, at 9:00 AM ET.

Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced the availability of the first paper produced by a research collaboration with Lawrence Berkeley National Laboratory (LBNL) and Los Alamos National Laboratory (LANL) and funded by the U.S. Department of Energy and the Defense Threat Reduction Agency (DTRA), which addresses the clear and critical need for pathogen agnostic diagnostics that can be quickly and effectively performed at point of need.